1-20 of 59
Manuel Hidalgo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial

Francesca Sarno, Jair Tenorio, Sofia Perea, Laura Medina, Roberto Pazo-Cid, Ignacio Juez, Rocío Garcia-Carbonero, Jaime Feliu, Carmen Guillen-Ponce, Pedro P. Lopez-Casas, Carmen Guerra, Yolanda Duran, José Francisco López-Acosta, Carolina Alonso, Estrella Esquivel, Ana Dopazo, Dipikaa Akshinthala, Senthil K. Muthuswamy, Pablo Lapunzina, Bruno Bockorny, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (2): 278–287.
https://doi.org/10.1158/1078-0432.CCR-23-4026
Published: 17 January 2025
View article titled, A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial
Open the PDF for A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial in another window
Includes: Supplementary data
Journal Articles

Facts and Hopes in Immunotherapy of Pancreatic Cancer

Bruno Bockorny, Joseph E. Grossman, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (21): 4606–4617.
https://doi.org/10.1158/1078-0432.CCR-21-3452
Published: 01 November 2022
View article titled, Facts and Hopes in Immunotherapy of Pancreatic Cancer
Open the PDF for Facts and Hopes in Immunotherapy of Pancreatic Cancer in another window
Journal Articles

Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer

Joseph E. Grossman, Lakshmi Muthuswamy, Ling Huang, Dipikaa Akshinthala, Sofia Perea, Raul S. Gonzalez, Leo L. Tsai, Jonah Cohen, Bruno Bockorny, Andrea J. Bullock, Benjamin Schlechter, Mary Linton B. Peters, Catherine Conahan, Supraja Narasimhan, Christine Lim, Roger B. Davis, Robert Besaw, Mandeep S. Sawhney, Douglas Pleskow, Tyler M. Berzin, Martin Smith, Tara S. Kent, Mark Callery, Senthil K. Muthuswamy, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 708–718.
https://doi.org/10.1158/1078-0432.CCR-20-4116
Published: 15 February 2022
View article titled, Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Open the PDF for Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop

Daniel D. Von Hoff, Gary M. Clark, Charles A. Coltman, Mary L. Disis, S.G. Eckhardt, Lee M. Ellis, Margaret Foti, Elizabeth Garrett-Mayer, Mithat Gönen, Manuel Hidalgo, Susan G. Hilsenbeck, John H. Littlefield, Patricia M. LoRusso, H. Kim Lyerly, Neal J. Meropol, Jyoti D. Patel, Steven Piantadosi, Dean A. Post, Meredith M. Regan, Yu Shyr, Margaret A. Tempero, Joel E. Tepper, Jamie Von Roenn, Louis M. Weiner, Donn C. Young, Nu V. Vu
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5472–5481.
https://doi.org/10.1158/1078-0432.CCR-21-1799
Published: 15 October 2021
View article titled, A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop
Open the PDF for A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop in another window
Includes: Supplementary data
Journal Articles

Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial

Bruno Bockorny, Teresa Macarulla, Valerya Semenisty, Erkut Borazanci, Jaime Feliu, Mariano Ponz-Sarvise, David Gutierrez Abad, Paul Oberstein, Angela Alistar, Andres Muñoz, Ravit Geva, Carmen Guillén-Ponce, Mercedes Salgado Fernandez, Amnon Peled, Marya Chaney, Irit Gliko-Kabir, Liron Shemesh-Darvish, Debby Ickowicz, Ella Sorani, Shaul Kadosh, Abi Vainstein-Haras, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5020–5027.
https://doi.org/10.1158/1078-0432.CCR-21-0929
Published: 15 September 2021
View article titled, Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial
Open the PDF for Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial in another window
Includes: Supplementary data
Journal Articles

Abstract S10-01: COVID-19 severity and outcomes in hospitalized patients with cancer at a New York City tertiary medical center: A matched cohort study

Gagandeep Brar, Laura C. Pinheiro, Michael Shusterman, Brandon Swed, Evgeniya Reshentnyak, Orysya Soroka, Frank Chen, Samuel Yamshon, John Vaughn, Peter Martin, Doru Paul, Manuel Hidalgo, Manish A. Shah
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S10-01.
https://doi.org/10.1158/1557-3265.COVID-19-S10-01
Published: 15 September 2020
View article titled, Abstract S10-01: COVID-19 severity and outcomes in hospitalized patients with cancer at a New York City tertiary medical center: A matched cohort study
Journal Articles

OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models

Myriam Fabre, Cristina Ferrer, Saioa Domínguez-Hormaetxe, Bruno Bockorny, Laura Murias, Oliver Seifert, Stephan A. Eisler, Roland E. Kontermann, Klaus Pfizenmaier, So Young Lee, María dM. Vivanco, Pedro P. López-Casas, Sofia Perea, Muhammad Abbas, Wolfgang Richter, Laureano Simon, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3420–3430.
https://doi.org/10.1158/1078-0432.CCR-19-2238
Published: 01 July 2020
View article titled, OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models
Open the PDF for OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies

Rodrigo A. Toledo, Elena Garralda, Maria Mitsi, Tirso Pons, Jorge Monsech, Estela Vega, Álvaro Otero, Maria I. Albarran, Natalia Baños, Yolanda Durán, Victoria Bonilla, Francesca Sarno, Marta Camacho-Artacho, Tania Sanchez-Perez, Sofia Perea, Rafael Álvarez, Alba De Martino, Daniel Lietha, Carmen Blanco-Aparicio, Antonio Cubillo, Orlando Domínguez, Jorge L. Martínez-Torrecuadrada, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3550–3559.
https://doi.org/10.1158/1078-0432.CCR-18-0103
Published: 31 July 2018
View article titled, Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
Open the PDF for Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies in another window
Includes: Supplementary data
Journal Articles

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

Andrew G. Hill, Michael P. Findlay, Matthew E. Burge, Christopher Jackson, Pilar Garcia Alfonso, Leslie Samuel, Vinod Ganju, Meinolf Karthaus, Alessio Amatu, Mark Jeffery, Maria Di Bartolomeo, John Bridgewater, Andrew L. Coveler, Manuel Hidalgo, Amy V. Kapp, Roxana I. Sufan, Bruce B. McCall, William D. Hanley, Elicia M. Penuel, Andrea Pirzkall, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2276–2284.
https://doi.org/10.1158/1078-0432.CCR-17-0646
Published: 14 May 2018
View article titled, Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <em>RAS</em> Wild-Type Metastatic Colorectal Cancer
Open the PDF for Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <em>RAS</em> Wild-Type Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Personalized RNA Medicine for Pancreatic Cancer

Maud-Emmanuelle Gilles, Liangliang Hao, Ling Huang, Rajesha Rupaimoole, Pedro P. Lopez-Casas, Emilia Pulver, Jong Cheol Jeong, Senthil K. Muthuswamy, Manuel Hidalgo, Sangeeta N. Bhatia, Frank J. Slack
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (7): 1734–1747.
https://doi.org/10.1158/1078-0432.CCR-17-2733
Published: 02 April 2018
View article titled, Personalized RNA Medicine for Pancreatic Cancer
Open the PDF for Personalized RNA Medicine for Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez-Garcia, Christophe Le Tourneau, Christophe Massard, Elena Garralda, Valentina Boni, Alvaro Taus, Joan Albanell, Marie-Paule Sablin, Marie Alt, Ratislav Bahleda, Andrea Varga, Christophe Boetsch, Izolda Franjkovic, Florian Heil, Angelika Lahr, Katharina Lechner, Anthony Morel, Tapan Nayak, Simona Rossomanno, Kevin Smart, Kay Stubenrauch, Oliver Krieter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1536–1545.
https://doi.org/10.1158/1078-0432.CCR-17-1588
Published: 02 April 2018
View article titled, First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Lars D. Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A. Tovar, Curt J. Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P. Lopez-Casas, Natalia Baños, Camino Menendez, Manuel Hidalgo, Vanessa Tassell, Richard Chao, Darya I. Chudova, Richard B. Lanman, Peter Olson, Lyudmilla Bazhenova, Sandip Pravin Patel, Carrie Graveel, Mizuki Nishino, Geoffrey I. Shapiro, Nir Peled, Mark M. Awad, Pasi A. Jänne, James G. Christensen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (21): 6661–6672.
https://doi.org/10.1158/1078-0432.CCR-17-1192
Published: 31 October 2017
View article titled, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <em>MET</em> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Open the PDF for Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <em>MET</em> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F. Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez-Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh-de Parseval, Tim Demuth, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5339–5348.
https://doi.org/10.1158/1078-0432.CCR-16-2923
Published: 15 September 2017
View article titled, Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma
Open the PDF for Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Treatment of Pancreatic Cancer Patient–Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin

N.V. Rajeshkumar, Shinichi Yabuuchi, Shweta G. Pai, Elizabeth De Oliveira, Jurre J. Kamphorst, Joshua D. Rabinowitz, Héctor Tejero, Fátima Al-Shahrour, Manuel Hidalgo, Anirban Maitra, Chi V. Dang
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5639–5647.
https://doi.org/10.1158/1078-0432.CCR-17-1115
Published: 14 September 2017
View article titled, Treatment of Pancreatic Cancer Patient–Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin
Open the PDF for Treatment of Pancreatic Cancer Patient–Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

Emiliano Calvo, Jean-Charles Soria, Wen Wee Ma, Tao Wang, Rastilav Bahleda, Anthony W. Tolcher, Diana Gernhardt, Joseph O'Connell, Robert Millham, Nagdeep Giri, Michael J. Wick, Alex A. Adjei, Manuel Hidalgo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1177–1185.
https://doi.org/10.1158/1078-0432.CCR-15-2301
Published: 28 February 2017
View article titled, A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
Open the PDF for A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract IA17: Application of PDX models to pancreas cancer research

Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): IA17.
https://doi.org/10.1158/1557-3265.PDX16-IA17
Published: 15 August 2016
View article titled, Abstract IA17: Application of PDX models to pancreas cancer research
Journal Articles

Abstract B44: When murine tumors are thought to be human: A drawback of patient derived xenografts.

Camino Menéndez, Beatriz Salvador, Manuel Muñoz, Natalia Baños, Francesca Sarno, Pedro P López-Casas, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B44.
https://doi.org/10.1158/1557-3265.PDX16-B44
Published: 15 August 2016
View article titled, Abstract B44: When murine tumors are thought to be human: A drawback of patient derived xenografts.
Journal Articles

Abstract B42: Patient-derived metastatic models of pancreatic cancer: An in-vivo system for modeling metastasis and preclinical drug screening

Spas Dimitrov, Manuel Muñoz, Natalia Baños, Camino Menéndez, Victoria Bonilla, Yolanda Duran, Rodrigo Toledo, Francesca Sarno, Javier Perales-Patón, Fátima Al-Shahrour, Pedro P Lopez-Casas, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): B42.
https://doi.org/10.1158/1557-3265.PDX16-B42
Published: 15 August 2016
View article titled, Abstract B42: Patient-derived metastatic models of pancreatic cancer: An in-vivo system for modeling metastasis and preclinical drug screening
Journal Articles

Abstract A36: Assessment of effectiveness and molecular markers of CDK4/6 inhibitor Palbociclib in Pancreatic Ductal Adenocarcinomas

Beatriz Salvador, Pedro P. López-Casas, Camino Menéndez, Natalia Baños, Francesca Sarno, Yin Min-Jean, Peter Olson, Todd VanArsdale, David J. Shields, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): A36.
https://doi.org/10.1158/1557-3265.PDX16-A36
Published: 15 August 2016
View article titled, Abstract A36: Assessment of effectiveness and molecular markers of CDK4/6 inhibitor Palbociclib in Pancreatic Ductal Adenocarcinomas
Journal Articles

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

Manuel Hidalgo, Carlos Plaza, Monica Musteanu, Peter Illei, Carrie B. Brachmann, Carla Heise, Daniel Pierce, Pedro P. Lopez-Casas, Camino Menendez, Josep Tabernero, Alfredo Romano, Xinyu Wei, Fernando Lopez-Rios, Daniel D. Von Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (21): 4811–4818.
https://doi.org/10.1158/1078-0432.CCR-14-3222
Published: 01 November 2015
View article titled, SPARC Expression Did Not Predict Efficacy of <em>nab</em>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Open the PDF for SPARC Expression Did Not Predict Efficacy of <em>nab</em>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial in another window
Includes: Supplementary data